Press Releases
Whether it’s a new product enabling ground-breaking research, a strategic partnership with a customer, or a charitable partnership that supports our mission, we’ve always got something going on. Below you’ll find our most recent press releases as well as a filter to further streamline your search.
May 29, 2024
MilliporeSigma Signs MoU with KAIST to Advance Scientific CollaborationMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with KAIST.
Apr 24, 2024
Apr 17, 2024
MilliporeSigma Inspires Students to Explore STEM Careers with 2024 Curiosity Cube TourMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, officially kicked off its global 2024 Curiosity Cube tour today in Darmstadt, Germany.
Apr 16, 2024
MilliporeSigma Launches First All-in-One Genetic Stability Assay to Accelerate Biosafety TestingMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, launched the first all-in-one, validated genetic stability assay of its kind.
Feb 28, 2024
Feb 14, 2024
Feb 13, 2024
Press Release Test AEM3-605Teaser text.
Jan 24, 2024
Dec 27, 2023
Dec 27, 2023
Dec 20, 2023
Oct 22, 2023
Oct 10, 2023
Oct 02, 2023
Sep 11, 2023
Aug 29, 2023
Jul 12, 2023
Merck Invests € 23 Million to Expand Cell Culture Media Production in Kansas, USALenexa, Kansas, USA facility becomes company’s largest dry powder cell culture media facility and Center of Excellence
Jun 06, 2023
MilliporeSigma Announces Proteologix as Winner of its North American Advance Biotech GrantMilliporeSigma announced that Proteologix US Inc. (“Proteologix”) has been selected as the North American winner of its 12th Advance Biotech Grant program.
May 31, 2023
Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine ManufacturersAccording to a recent study sponsored by Merck, a leading science and technology company, mRNA technology is a “game-changer” for Asia-Pacific (APAC) vaccine manufacturers. Nearly 40 manufacturers participated in the survey.
May 31, 2023
Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in ScotlandResponds to global demand for biosafety testing for drug development and commercialization. Expansion creates nearly 500 new jobs in Glasgow and Stirling. Company’s investment to boost global testing capacity now tops € 350 million since mid-2022.
May 03, 2023
The Life Science Business of Merck KGaA, Darmstadt, Germany Signs MoU with Ministry of Trade, Industry & Energy and Daejeon City for New Asia Pacific BioProcessing Production Center in South KoreaMilliporeSigma has announced that the Life Science business sector has signed a non-binding MoU) with the Ministry of Trade, Industry and Energy (MOTIE) and Daejeon City for a new Asia-Pacific BioProcessing Center.
Apr 26, 2023
MilliporeSigma Kicks Off 2023 Curiosity Cube Mobile Lab TourOver 250 events expected to reach more than 45,000 future scientists on two continents. Hands-on experiments to focus on the impact of contamination on the planet and everyday life.
Apr 24, 2023
MilliporeSigma Launches Ultimus® Film to Offer Superior Strength and Leak Resistance in Single-use AssembliesMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the launch of its Ultimus® Single-Use Process Container Film.
Mar 27, 2023
MilliporeSigma Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry EducationPartnership to support Beyond Benign’s online learning platform and higher education program
Dec 08, 2022
MilliporeSigma Signs MoU with Synplogen to Accelerate Development and Manufacturing of Viral Vector-based Gene Therapy ApplicationsMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum of Understanding (MoU) with Synplogen.
Dec 06, 2022
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems AcquisitionMilliporeSigma a leading science and technology company, has acquired Massachusetts-based Erbi Biosystems.
Nov 25, 2022
AEM2-823-PR - - MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-UpMilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Nov 16, 2022
MilliporeSigma Invests € 290 Million in U.S. Drug Safety Testing CapacityMerck invests more than € 290 million in its biosafety testing capacity at Rockville, Maryland, USA.
Nov 07, 2022
MilliporeSigma Announces Collaboration with Biotheus to Accelerate Drug Submission and Approval Process for Biopharmaceutical Industry in ChinaMilliporeSigma, a leading science and technology company, today announced a collaboration with Biotheus.
Nov 01, 2022
Oct 04, 2022
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO ServicesThe Life Science business of Merck KGaA, Darmstadt, Germany, has opened a commercial facility for its new Millipore® CTDMO Services offering at the company’s site in Martillac, France.
Sep 28, 2022
Sep 21, 2022
Sep 21, 2022
MilliporeSigma Announces Opening of New € 29 Million Biologics Testing Center in ShanghaiMilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced the opening of a viral clearance (VC) laboratory as part of the first building phase of its new € 29 million China Biologics Testing Center.
Sep 08, 2022
MilliporeSigma Invests More Than € 130 Million to Strengthen Manufacturing Capabilities in Molsheim, FranceMerck, a leading science and technology company, strengthens its manufacturing capabilities for single-use assemblies
Aug 08, 2022
MilliporeSigma Becomes One of the First CDMOs to Provide Full Viral Vector Offering with Launch of VirusExpress® 293 Adeno-Associated Virus Production PlatformMilliporeSigma, a leading science and technology company, has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform, making it one of the first CDMOs and technology-developers to provide a full viral vector manufacturing offering.
Jul 19, 2022
New Solar Panels at MilliporeSigma’s Wisconsin, USA Site Add Renewable Energy to Power Grid7,000 solar panels produce energy to power 700 homes, Part of We Energies’ “Solar Now” program, bringing more renewable energy to Wisconsin, Reinforces the company’s long-term commitment to renewable energy.
Jul 18, 2022
Life Science Business of MilliporeSigma Breaks Ground on Company’s First Lateral Flow Membrane Production Facility in the United StatesNew facility to manufacture the company’s Hi-Flow™ Plus lateral flow membrane used in rapid diagnostic test kit manufacturing, including Covid-19.
Jun 29, 2022
MilliporeSigma Signs MoU with Lotte Biologics for Biologics ManufacturingMilliporeSigma signed a non-binding Memorandum of Understanding (MoU) with the new biologics business of Lotte Group, outlining a planned collaboration to establish Lotte’s biologics manufacturing capabilities in the USA.
Jun 22, 2022
MilliporeSigma Opens € 59 Million CDMO Facility to Address Demand for Critical Cancer TherapiesMilliporeSigma, announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, Wisconsin.
Jun 14, 2022
MilliporeSigma Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream ProcessingMilliporeSigma collaborates with Agilent Technologies to advance Process Analytical Technologies (PAT).
May 28, 2022
Press Release Headline - NAPress Release Teaser - NA
May 23, 2022
MilliporeSigma Invests More Than €440 Million and Expands its Membrane and Filtration Manufacturing in IrelandThe investment, which is the largest in a single site ever for the Life Science business sector, significantly increases membrane manufacturing capacities and enables the construction of a new filtration manufacturing facility.
May 18, 2022
MilliporeSigma Announces the Expansion of Hands-On Science Education Program with Kick-off of Global Curiosity Cube® Mobile LabMilliporeSigma today announced that the Life Science business further enhanced its commitment to Science, Technology, Engineering and Math (STEM) education, with the launch of its 2022 Curiosity Cube® mobile science lab in Europe and North America.
Apr 28, 2022
MilliporeSigma Announces Investment of Approximately € 100 Million to Accelerate Single-Use Manufacturing in ChinaMilliporeSigma’s First Asia Pacific Mobius® Single-Use Manufacturing Center in Wuxi, China
Apr 21, 2022
MilliporeSigma Transforms Media Preparation and Dispensing with New ReadyStream® SystemReadyStream® system offers automated media preparation to conveniently provide a large volume of preheated media, eliminates five time-consuming steps.
Apr 14, 2022
MilliporeSigma’s ZooMAb® Antibodies Earns First-Ever ACT Label from My Green LabZooMAb® antibodies first-ever antibody to be recognized for low-environmental impact by My Green Lab
Apr 12, 2022
Press Release 1304 MilliporeSigma NA HeadlinePress Release 1304 MilliporeSigma NA Teaser
Apr 05, 2022
MilliporeSigma Announces Acquisition of MAST® Platform from Lonza, a Leading Automated Bioreactor Sampling System to Advance BioProcessing CapabilitiesMilliporeSigma to become the first company to offer a fully integrated ecosystem for advanced process technologies.
Mar 27, 2022
Feb 28, 2022
Press Release Headline - NAPress Release Teaser - NA
Feb 23, 2022
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-UpMilliporeSigma, the U.S. and Canada Life Science business sector of Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced the closing of the transaction to acquire Exelead, following regulatory clearances and the fulfillment of other customary closing conditions, for approximately USD 780 million in cash. The business combination is expected to enable the Life Science business to provide its customers with comprehensive end-to-end contract development and manufacturing organization (CDMO) services across the mRNA value chain. The Life Science business plans to further invest over € 500 million to scale up Exelead’s technology over the next ten years.
Feb 15, 2022
MilliporeSigma and Waters to Collaborate on Extractables and Leachables Reference LibraryMilliporeSigma's Life Science business sector has entered into a collaboration with Waters Corporation to build and expand an Extractables and Leachables (E&L) Reference Library to include ion mobility measurements
Feb 10, 2022
NA HeadlineNA Teaser text
Feb 07, 2022
MilliporeSigma Announces Organizational Transformation to Strengthen CDMO Offering and Accelerate Future GrowthMilliporeSigma today announced several organizational changes and a new operating model to support the long-term growth strategy of the Life Science business sector and to better serve the evolving needs of its global customers.
Jan 26, 2022
MilliporeSigma Announces MoU with ID Pharma to Accelerate Development and Manufacturing of Gene TherapyMilliporeSigma, a leading science and technology company, today announced that the Life Science business sector signed a non-binding Memorandum of Understanding (MoU) with ID Pharma, the advanced medical business within I’rom Group, outlining its planned support of the development and manufacturing of leading-edge gene therapy.
Dec 26, 2021
Press Release 2712 MilliporeSigma NA HeadlinePress Release 2712 MilliporeSigma Teaser NA
Dec 15, 2021
Dec 13, 2021
Press Release 1312 MilliporeSigma - NAPress Release 1312 MilliporeSigma - Teaser NA
Nov 29, 2021
Press Release 3011 MilliporeSigma Headline - NAPress Release 3011 MilliporeSigma Teaser - NA
Nov 24, 2021
MilliporeSigma’s New VirusExpress™ Platform Speeds Development of Cell and Gene TherapiesMilliporeSigma has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform.
Nov 14, 2021
Press Release 1511 MilliporeSigma Headline - NAPress Release 1511 MilliporeSigma Teaser -NA
Nov 10, 2021
Press Release 1111 MilliporeSigma Headline - NAPress Release 1111 MilliporeSigma Teaser -NA
Jul 15, 2021
Press Release MilliporeSigma 1606 Headline NAPress Release MilliporeSigma 1606 Teaser NA
Jul 15, 2021
Press Release 0714 MilliporeSigma - NAPress Release 0714 MilliporeSigma Teaser - NA
Jul 15, 2021
Press Release MilliporeSigma 3006 - NAPress Release MilliporeSigma 3006 Teaser
Jun 15, 2021
Press Release MilliporeSigma 2705 - Headline NAPress Release MilliporeSigma 2705 Teaser NA
Oct 15, 2020
MilliporeSigma’s New VirusExpress™ Platform Speeds Development of Cell and Gene TherapiesMilliporeSigma has bolstered its viral vector manufacturing capabilities with the launch of its VirusExpress™ Lentiviral Production Platform.
Mar 03, 2020
MilliporeSigma’s New LANEXO® System to Improve Scientists’ Productivity in the LabMilliporeSigma today launched its LANEXO® Lab Inventory, Safety and Compliance Management System, a new digital laboratory informatics solution designed to drastically reduce time in labs and improve data quality and traceability.
Dec 10, 2018
MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent ModelsMilliporeSigma, a leader in genome editing, today announced a strategic alliance in the CRISPR/Cas9 rodent model market with France-based biotechnology company genOway.
Para seguir leyendo, inicie sesión o cree una cuenta.
¿No tiene una cuenta?